Insights
Insights on health, access and innovation
Read practical thinking from Newmarket Strategy on the policy, access, reimbursement and health system issues shaping healthcare and life sciences.
Part 2: Asset level commercial strategies alongside national level system change
Innovative commercial strategies to achieve an optimal net price have never been more critical – and achieving them will demand a higher appetite for risk from all parties.
Part 1: How to influence national systems to help mitigate MFN headwinds
The UK example demonstrate that national system reform is achievable. But it requires the use of a new playbook.
NHS pharmaceuticals negotiator to join Newmarket Strategy
Health and life sciences consultancy, Newmarket Strategy, has added another NHS and government leader to its top team. Robert Kettell, currently the NHS’s Director of Medicines Negotiation, will join Newmarket as…
Newmarket Strategy acquires Visible Analytics to complete its full-service market access offer
Newmarket Strategy, a specialist healthcare and life sciences consultancy, announces today the successful acquisition of Visible Analytics, experts in Health Economics and Outcomes Research (HEOR) and data analytics.
The Future of Healthcare and Life Sciences Research Conference 2025
The Future of Life Sciences event brought together leaders from across the NHS, government, academia, and industry to tackle one of the UK’s greatest opportunities—and challenges: unlocking the full potential of…
The value of commercial clinical trials
One of the main messages outlined in the ‘Lord O’Shaughnessy review on commercial clinical trials’ was the economic and financial value to the UK. The review’s own research showed that…
Events
